What is 510(k)?
A 510(k) is a premarket submission made to the FDA to demonstrate that a new medical device is substantially equivalent to a legally marketed predicate device. "Substantially equivalent" means the new device has the same intended use and the same technological characteristics — or different technological characteristics that do not raise new questions of safety and effectiveness.
Unlike the Premarket Approval (PMA) process — which requires clinical evidence of safety and effectiveness — a 510(k) clearance does not require the device to have undergone any clinical trials. The manufacturer simply needs to demonstrate equivalence to an already-marketed device.
Key distinction: A device that receives 510(k) clearance is cleared — not approved. These words carry very different legal and scientific meanings. Cleared means the FDA has determined substantial equivalence; it does not mean the FDA has found the device to be safe or effective through clinical testing.
For more on this distinction, see FDA Cleared vs. Safe: The 510(k) Loophole.
Historical Context
The 510(k) pathway was created by the Medical Device Amendments of 1976 — a law passed after a series of high-profile device failures in the early 1970s, including the Dalkon Shield IUD. Congress intended to establish a rigorous premarket approval system for medical devices.
The 510(k) provision was written as a temporary grandfather clause. Congress recognized that thousands of devices already on the market in 1976 could not realistically go through full PMA review. The 510(k) pathway was meant to handle those legacy devices — not to become the dominant pathway for all new devices going forward.
Medical Device Amendments enacted. 510(k) created as a temporary grandfather clause for pre-existing devices.
510(k) begins expanding beyond its original scope as industry uses it for new devices claiming equivalence to grandfathered predicates.
FDA Modernization Act streamlines 510(k) process further, reducing review times and paperwork requirements.
IOM report recommends replacing the 510(k) system entirely. Industry lobbying defeats the recommendation.
FDA launches 510(k) modernization initiatives. GAO reports find ongoing gaps in device oversight.
PLOS ONE study documents predicate creep in robotic surgical devices, confirming long-standing concerns about the predicate chain mechanism.
As legal analyst Kurt Karst has documented, the 510(k) provision "was meant as an exception — in essence a little loophole" that became the rule. See The Medical Device Amendments of 1976: The Statute That Went Awry.
The Predicate Chain Problem
The predicate chain problem arises from the logic of substantial equivalence. A device can be cleared by demonstrating equivalence to a predicate — but that predicate may itself have been cleared by reference to an earlier predicate, which was cleared by reference to an even earlier device, and so on.
This creates chains of cleared devices stretching back decades to a 1976 "preamendment" device. The original predicate may have been a simple mechanical tool; the device at the end of the chain may be a sophisticated computer-controlled robotic surgical system. At each step, the incremental change appeared small — but the cumulative effect is enormous.
The risk: If any device in the predicate chain was later recalled, found to be dangerous, or was itself improperly cleared, every subsequent device in that chain may also be at risk. A 2011 case saw the FDA rescind the clearance of a device and issue letters to hundreds of manufacturers who had used it as a predicate.
Predicate Creep — New Research
In 2023, researchers Charlotte Lefkovich and Sandra Rothenberg published a landmark study in PLOS ONE: Identification of Predicate Creep Under the 510(k) Process: A Case Study of a Robotic Surgical Device.
The study traced the clearance history of the Intuitive Surgical Da Vinci Si Surgical System — finding 2,618 device instances across 15 different product codes. The Da Vinci Si, a sophisticated computer-controlled robotic surgical system, was cleared through comparison to devices that included simple endoscopes, electrosurgical cutting tools, and cryosurgical units.
The authors propose a new methodology — using product codes and regulatory classification codes — to systematically identify predicate creep in the 510(k) database. Their findings confirm that predicate creep is both real and measurable.
Read the full paper: Lefkovich & Rothenberg, PLOS ONE (2023)
Pathway Comparison
| Pathway | 510(k) | PMA | De Novo | HDE |
|---|---|---|---|---|
| Device Class | Class I, II | Class III (high risk) | Class I or II (novel) | Class III (rare disease) |
| Clinical Trials Required? | No | Yes — mandatory | Sometimes | Abbreviated |
| Standard | Substantial equivalence | Reasonable assurance of safety & effectiveness | New classification with controls | Probable benefit outweighs risk |
| FDA Review Time | ~90 days | 180–360+ days | ~120 days | 180 days |
| Cost | Low | High ($$$) | Moderate | Reduced fees |
Industry Lobbying
The medical device industry has spent hundreds of millions of dollars lobbying to preserve and expand the 510(k) pathway. The pathway's appeal is straightforward: it is significantly cheaper and faster than PMA approval, and it requires no clinical evidence of safety or effectiveness.
Former FDA Commissioner David A. Kessler, M.D. (1990–1997) has been particularly direct: "The problem we have is that when it comes to medical devices we built a system that doesn't work. That [510(k)] provision which was meant as an exception — in essence a little loophole — that exception became the rule."
Investigative journalist Jeanne Lenzer documents this lobbying in depth in The Danger Within Us: "There simply are no truly independent sources of research in the US. Industry funding has extended its reach into every sector."
A 2012 BMJ investigation documented specific mechanisms of industry influence on the FDA and on Congress. See the full BMJ report.
Reform Efforts
Multiple organizations — including the Institute of Medicine, the Government Accountability Office, Public Citizen, and academic researchers — have called for fundamental reform or replacement of the 510(k) system.
The FDA itself has launched several modernization initiatives, including the 510(k) Program Modernization updates and increased post-market surveillance requirements. The FDA's ongoing efforts are documented at FDA.gov.
Reform proposals have generally focused on:
- Limiting the age of acceptable predicates (cutting off chains that trace back to 1976 grandfathered devices)
- Requiring clinical data for high-risk devices cleared through 510(k)
- Strengthening post-market surveillance and adverse event reporting
- Expanding the De Novo pathway as an alternative for novel low-to-moderate risk devices
Current status: Despite decades of calls for reform, the 510(k) pathway remains largely intact. Industry lobbying, combined with the pathway's economic efficiency, has consistently defeated proposals for more rigorous premarket requirements.